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Introduction
A young woman walks into her doctor’s office complaining of 
what seems to be a pimple that does not go away. She initially 
treated it with over counter creams, then a facial and many der-
matologist visits. Upon a more extensive examination the spe-
cialist realized that this was not the average case of adolescent 
acne and ordered blood work. The test revealed that this girl 
has type-one diabetes. Her plans to go to college were placed 
on hold and her life completely changed. What if diabetes didn’t 
have to be a life altering disease? What if glucose monitoring 
and insulin injections were replaced with a one-time stem cell 
therapy that could replace the damaged cells? This example did 
occur and the girl is being treated with subcutaneous insulin 
infusion therapy. Stem Cell Research has not reached this break-
through but the hope is that in the future stem cells will be used 
to test medical treatments and replace cells lost by devastating 
diseases that currently have no sustainable cure. 
The first several divisions of the mammalian fertilized oocyte 
give rise to totipotent cells. These cells can form cells in the 
placenta, embryotic sack, and any cell in the body. Once cells are 
designated for the body they are termed pluripotent cells. These 
embryotic stem cells have virtually limitless potential and are an 
invaluable resource for the biomedical community. Along with 
the importance of these cells arises a responsibility of using 
them correctly. The process of understanding how these stem 
cells work and the services they can provide has not been an 
easy feat. This battle has been fought in both the courtrooms 
and laboratories. The legal system bears the responsibility of 
creating a system in which guidelines are being followed and 
ethics upheld. This is an ongoing battle, and there is no under-
mining this work. Regardless of several ongoing debates and 
some legal verdicts, the biomedical community is addressing 
stem cell research, cell regeneration, and organ construction 
from two different perspectives. There is ongoing promising 
research being done on organ and cell regeneration with the 
use of somatic stem cells. Specific mature, undifferentiated, adult 
cells are reprogramed to function as stem cells and referred to 
as induced pluripotent stem cells (iPSC). These cells, generally 
found in the epithelial cells  of an adult organ, have already been 
assigned a task and are therefore limited to the regeneration of 
that particular cell or organ. However, being that they are ex-
tracted from the patient, it is assumed, although not tested, that 
these cells will face less rejection after implantation because 
of the body’s familiarity with the cells. An alternative form of 
adult stem cells is activation of somatic stem cells (Stem Cell 
Information, n.d.) within the body. These cells reside within a 
healthy body and function as a natural maintenance system by 
regenerating aged or damaged tissue and replacing lost cells. 
Examples of the somatic stem cells are cord blood and bone 
marrow. The third of these general stem cell approaches allows 
for more potential but at a greater risk; pluripotent embryotic 
stem cells (ESC) can be used to create any cell or organ but at 
a higher probability for tumor growth. There are several distinct 
differences between embryotic and adult stem cells. Adult stem 
cells are rare cells that require extraction, isolation, and then in 
vivo cell culturing, to multiply. This cell culture process has not 
fully developed and is a great deal more complicated than the 
growth of ESCs (Herberts et. al. 2011., Shanthly et. al. 2006).
This paper will explore the potential of regenerating tissue by 
means of pluripotent stem cells, as well as discuss literature on 
growth of these cells to build tissues and replace cells. Upon ex-
ploring the processes of in vitro and in vivo differentiation, in 
both induced pluripotent stem cells (iPSC) and human embryonic 
stem cells (hESC), one can question the technology needed to 
operate these cells. Is it possible to limit stem cells to differen-
tiate, as they would in utero, to create a select tissue or organ?
Abstract
It would seem that differentiation of stem cells is the remedy of modern times. Yet stem cell research is more complex 
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Methods
This document was amassed by referencing original research and 
peer reviewed scholarly articles. US government websites and 
portions of scholarly articles were accessed to gain knowledge 
about the background, history, and general methods involved in 
stem cells therapies. Specific topic information, regarding the re-
search question, was collected, reviewed, and analyzed. Google 
Scholar, and databases that are made accessible through the 
Touro College online library, such as Proquest and Ebsco, were 
used to search and access documents related to the research 
topic. The following are examples of key words were used: stem 
cell and apoptosis, c-myc, tumorigenic factors, in vivo growth, 
nodal signaling. There was no discrimination made regarding the 
date of publication on articles. 
History
Initial stem cell research dates back to 1870, with in vitro fertil-
ization of an oocyte. Any form of promising finding were slow 
until research intensively propelled in the late nineteen seven-
ties. Notable accomplishments include cloning of mammals in 
1997 and development of the first stem cell culture in 1998. 
The virtually simultaneous discovery of cloning and stem cells 
were the building block of forthcoming research. Stem cells cul-
tured in today’s laboratories are removed from the blastocyst 
early in differentiation and frozen in their state until they are 
differentiated into the cells required for a specific medical ther-
apy (Shanthly et. al. 2006). Research is ongoing and promising; 
the biomedical community has only scratched the surface of 
the untapped potential of stem cells. There are various issues 
and setbacks that are limiting stem cell potential (Stem Cell 
Information, n.d.). 
Stem cell research raised sharp scientific, technological, ethi-
cal, and political controversies. The United States federal and 
state governments enforced laws to enhance and restrict actual 
stem cell research. States such as Florida and New York agree 
to provide state funding while other states such as Arkansas 
and Michigan have placed bans on the creation and use of ESC 
for biotech research (Vestal 2008). Some forms of stem cell 
research and experimentation are more disputed than others; 
stem cells derived from oocytes are more controversial than 
induced adult cells. For example, in 2006 the Senate passed a 
law allowing federal money to benefit the specific research of 
iPSC, umbilical blood and bone marrow treatments but not 
ESC. However, in 2011 President Obama removed all bans that 
restricted federal funding from being assigned to new lines of 
embryotic stem cells. Regardless of the origin of the cell, human 
stem cells research raises ethical sensitivities. The ethical poli-
cies are continuously evolving and the biomedical community is 
attempting to overcome the challenges to ensure that research 
is carried out in an appropriate manner (Levin et. al. 2013).
In addition to legal constraints the anatomical components that 
comprise stem cells are intrinsically a hindrance. The same fac-
tors, enzymes, and transcription that insure the cell’s ability for 
self-renewal cause biomedical complications (Li et. al. 2015).
Differentiations
Some mammalian tissues, such as the skin and liver, have the 
ability to regenerate yet others cannot. The capability of bioen-
gineering and sustaining all organs, regardless of their regenera-
tion factor, will be invaluable; this can ultimately circumvent the 
transplant system ensuring that patients don’t die waiting for an 
organ. Regeneration capability is reliant on stem cells. For the 
purpose of this paper stem cells are divided into two catego-
ries, embryonic stem cells (ESC) and induced pluripotent stem 
cells (iPSC). In more recent years, researchers have developed 
methods of directly reprograming differentiated cells to pro-
duce iPSC. iPSCs are rare and found in only some differentiated 
tissues throughout the human body. A common use for iPSC 
is bone marrow transplants to fight leukemia. Although only 
one in every one hundred thousand cells is stem cell, advanced 
techniques allow for harvesting and collecting those cells in 
concentration to be donated by injecting the donor with colo-
ny-stimulating factor 3 (CSF 3). This glycoprotein stimulated the 
bone marrow to produce more stem cells; a necessary tool to 
collecting these otherwise dispersed cells. Such techniques can 
be used to collect adult stem cells but the process is tedious and 
does not allow for the unlimited potential hESC offer (Shanthly 
et. al. 2006). Although iPSC involves complications, such as the 
complexity of collection, it also provides therapeutic potential 
because these cells are harvested from a patient’s own cells. This 
can alleviate tissue and cell rejection complications. 
Since adult stem cells cannot give rise to all cells and tissues 
in the body, the ideal regenerative cell is embryotic stem cell. 
There are three different forms of embryonic stem cells used 
for medical research. The foremost method, true embryotic 
stem cells, is made from fertilized eggs generally donated by 
patients undergoing in vitro fertilization. Somatic cell nuclear 
transfer (ntES cell) is the process of creating an embryotic cell 
by inserting the nucleus of a general human cell into an egg cell. 
Although this technology has not been tested on higher mam-
mals, it can be of great use because the nucleus of the cell will be 
a genetic match to the patient. The third form of ESC, not ready 
for clinical use, is called parthenogenetic embryonic stem cells 
(pESC). Through the process of parthenogenesis, an unfertilized 
egg is stimulated into differentiating as an embryotic cell would 
(Shanthly et. al. 2006). 
Stem Cell Links to Tumorigenic Cells
Regardless of the types of ESC, these stem cells are derived from 
the core of mammalian blastocysts and can multiply infinitely 
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and differentiate into three germ layers: mesoderm, endoderm 
and ectoderm.  However, there are stem cells that have been 
documented to have significantly more genetic mutations as 
they grow in vitro. Research performed on zebra fish indicates 
that nodal signaling and pathways are found in both metastasized 
cancerous cells and embryotic stem cells yet not in healthy skin 
cells (Topczewska et. al. 2006). Nodal proteins are growth fac-
tors important to pattern formations needed for the embryotic 
differentiation, specifically as it relates to the formation of the 
mesoderm and endoderm .(Shen 2007). Activation of the nodal 
pathways is tightly regulated and prompts self-gene inscription 
with positive and negative feedbacks .(Cheng, Sun, 2014). The 
similarities between ESC and tumorigenic cells may lead to dis-
coveries that can limit the association between stem cells and 
cancer. Nodal signaling pathways are not the only unique link 
between stem cells and metastasized tumor cell; telomerase is 
an enzyme that facilitates growth and development of DNA in 
ESC but also found in upwards of fifteen times more often in 
cancer cells than in healthy cells .(Hiyama, Hiyama, 2007).
Nonsense-mediated mRNA decay (NMD) is been known to 
clean RNA in order to protect from early termination. At the 
PTC site, the location where early termination would com-
mence, the NMD complex is assembled. This complex balances 
and regulates the proteins and is essential for homeostasis and 
overall survival of not only the embryonic cell, but organisms as 
a whole. One factor of the NMD complex is Smg5, this factor 
is involved in telomere and telomerase maintenance. Thus this 
NMD factor and Telomerase protein are both essential compo-
nents that regulate cell viability. They may cause cell fatality or 
paradoxically, cancer (Li et. al. 2015).
Understanding the similarities between these cells help with 
limiting ESC. This process is called clinical transitions; scientific 
knowledge is gathered, understood and then turned into medi-
cal treatments. Regardless of these setbacks, the utility of these 
cells should not be undermined; simple laboratory practices 
such as freezing can assist with excess cell growth. Chemicals 
have been tested to determine if ESC can be treated to induce 
certain forms of apoptosis. Apoptosis is the shrinking of a com-
plete cell and its membrane. Apoptosis differs from the generic 
form of cell death by the fact that it does not leave residue. 
Excess cell components that did not shrivel; undergo phago-
cytosis. The purpose of these chemicals would be to generate 
cell death and on the specific component of the cell that may 
lead to complications, while leaving the remainder of the stem 
cell unharmed. Research performed on these compounds and 
chemical were published in 2012 and these findings claim to 
identify compounds that altered the viability of ESC (Conesa 
et. al. 2012).
Research In Vivo/ In Vitro
A ten-year research program beginning in the late 1980’s studied 
soft tissue engineering using totipotent stem cells. The experi-
ment used mouse embryotic stem cells to attempt to build lym-
phatic tissue, among other structures. Prior to commencement 
the researchers set out to establish what would be an ideal 
environment for embryogenesis. Building tissues in vivo requires 
an environment that mimics all aspects of uterus or in vitro de-
velopment; components such as nutrient and culture conditions 
are key. However, the physical creation of such an environment 
is quixotic, at best (Chen et. al. 1997, Shanthly et. al. 2006). A 
later study characterizes the complexity of stem cells by ex-
plaining the conditions for maintaining undifferentiated status. 
This study dictates that FGF2 and conditioned medium (CM) 
support hESC in an undifferentiated state. In 2005 undifferen-
tiated hESC were maintained with either FGF2 or CM. These 
stem cells remained in undifferentiated colonies apposed to the 
hESC that were maintained without these factors. Maintenance 
of the undifferentiated cells is an extremely delicate process, 
indicating that the steps from that point forward, toward proper 
differentiation, is that much more complex (Sumi et. al. 2007, 
Umar et. Al. 2014).
Development of any tissue, regardless of its origin requires 
three steps: cell differentiation, complex tissue formation, and 
the building of a three-dimensional, three-layered germ celled 
organ (Chen et. al. 1997). The most complex portion of com-
plete in vitro embryogenesis is the maintenance of a live culture 
throughout this process. As it is with a fetus, tissues, and organs 
can only function if the fetus is alive. Considerable research has 
been completed, and is ongoing, on many different forms of tis-
sue growth. To better understand the processes of building cells 
and tissues with stem cells, this paper will only be discussing 
two different tissues developed in culture, cardiac myocytes and 
lymphoid tissues. The decision to use these specific examples is 
based on varied dates of the research and the difference in tis-
sue complexity, due both to function and development of each 
cell.
Cardiac Myocytes
The differentiation of stem cells to cardiac myocytes is a rath-
er complex. Cardiac muscle is a prime example of a complex 
tissue due to the various forms of specific muscular tissues 
and their functions as it relates to an efficiently operating 
heart. Cardiac tissue is made up of interlocking, single nuclei, 
striated, muscle fibers. The unique and complex aspect of this 
tissue includes the intercalated disc, which assist in conduction 
speed, and autorythmicity, the ability to set its own contrac-
tions.  Research published in April of 2011 suggests promising 
potential of differentiation of cardiac myocytes from hESC. By 
inhibiting Bone Morphogenic Proteins (BMP), a growth factor, 
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during cardiac differentiation, cardiogenesis is initiated.  This 
step is far from the only one that is needed to allow for ESC 
to be transplanted for therapeutic uses. Additional research 
is required such as the study of the regulation of retinoid sig-
naling, the key that defines the difference between ventricular 
and arterial myocytes (Zhang et. al. 2011, Hartman et. al. 2014).
Lymphatic Tissue
The microenvironment needed for embryogenesis is delicate. 
Being that lymphoid cells develop toward the end of this pro-
cess, it was difficult to assume that the microenvironment need 
for ES cultures could be sustained until that point. Initiation of 
the research began with mice. Through the use of viral vectors, 
oncogenes were inserted and developed in vivo to produce B 
and T cells.  Many attempts and adjustment were made. The gen-
eration of B and T cells from lymphatic tissue was rare at the 
time publication of this journal but at the end of the research it 
was confirmed that lymphoid precursor cells could be derived 
from ESC. These years of research, experiments, and analysis of 
data only begins to explain the complexity of building tissues, 
regardless of their origin (Chen et. al. 1997).
Complications
Regardless of the difficulty of building tissues from stem cells 
and the improvements to cell cultures explained in cardiomy-
ocytes formation, there are other complications that require 
attention. In fact, some stem cell therapies such as bone marrow 
transplants with somatic stem cell, do not involve the intricate 
complexities that tissue growth requires. Yet even these ther-
apies must be addressed as it relates to the other risk factors 
involved in such a therapy. Risk factors begin in procurement 
and linger through the many phases involved, beginning with cul-
turing and injection. Subsequent to any initial success, long-term 
affects must be analyzed. There is deficient clinical experience 
in embryonic and adult stem cells. This lack of experience is an 
inevitable aspect of relatively new, current, and ongoing research 
and results in a variety of complications, after stem cell injection 
(Herberts et. al. 2011). 
General observations of the three most common forms of stem 
cells are summarized in Table 1. Improved comprehension of 
the differences and characteristics of these cells will assist in 
establishing their risk analysis.
An example of a consequence is tumor formation. This is a 
known complication that is being investigated from different 
standpoints. Understanding cell growth and death is crucial to 
such an analysis. The Myc gene family encompassed both factors. 
It is for that reason that this paper uses c-Myc as an example 
of a protein that may help limit tumor genesis. In addition fifty 
percent of tumor formation found in mouse research of iPSC is 
attributed to c-Myc.
Tumor Formation
The basic and universal self-renewal factors that assist in 
feedback and feed forward loops is Oct4, Sox2 and Noanog. 
However, the Myc gene family is additional self-renewal proteins 
and factors that affect intrinsic stem cell existence and apoptosis. 
Research published in 2007 investigated the function of c-Myc in 
stem cells regulation, differentiation, and apoptosis. Initially the 
tests were performed on mouse stem cells and later applied to 
hESC. It was widely known that that c-Myc is required to reg-
ulate normal cell development. However, the application of this 
factor in hESC regulation was confirmed and verified as being 
expressed as three different factors of the same family (Myc, 
Mycn, MycL1). Each of these Myc proteins were tested and found 
in the mRNA of hESC. Furthermore, just as c-Myc was present in 
regulation of mice cells, it was traced in undifferentiated human 
stem cells. Testing of this protein suggests that c-Myc is a factor 
of self-renewal. This research further investigated if c-Myc would 
also affect apoptosis and differentiation (Sumi et. al. 2007).
The properties of the c-Myc protein are best explained when 
looking at cancer cells. The protein factor c-Myc is found to be 
uncontrolled in end-stage cancers. This overexpression in tum-
origenic cells helps explain the role it plays in normal cell growth, 
stem cell proliferation, differentiation, and apoptosis. Even prior 
to a complete discovery of the potential of c-Myc, it was known 
that increased levels of c-MYC indicated the initiation of cell 
death. There are various pathways in which apoptosis is initiated. 
The first is by the regulator p53 ultimately activating BAX. The 
second is activation of PI3’K-AKT. The third and final pathway to 
cell apoptosis is through cell ligations that activate c-Myc. The 
activation and increase of this protein then caused apoptosis 
(Prendergast 1999).
ESC: iPSC: SSC:
Derived from inner 
mass of blastocyst
Derived from somatic 
cells
Isolated from postnatal 
adult tissue
Allogenic material
Autologous or Allogen-
ic material
Autologous or  
Allogenic material
Pluripotent Pluripotent Multipotent
Can differentiate into 
all three germ cells
Can differentiate into 
all three germ cells
Can differentiate to 
limited cell types.
Self-renewal Self-renewal Limited Self-renewal
Indefinite Growth Indefinite Growth Limited Lifespan
Significant Teratoma 
Risk
Significant Teratoma 
Risk
No Teratoma Risk
Serious Ethical Issues Serious Ethical Issues Serious Ethical Issues
Immuno-priviliged Not Immuno-priviliged Unpredictable
(Prendergast 1999)
Table 1
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Being that this factor plays a role both in the differentiation of 
stem cells and the death of tumor cells, it must be assumed 
that investigations on regulation of this protein may be vital to 
advancements in stem cell therapy. With better control of this 
protein a clinical laboratory scientist may be able to use it in 
either furthering the differentiation of cells or leaving them in an 
undifferentiated state when deemed necessary. The link between 
the Myc gene family and oncogenic cells will additionally assist 
with the considerable complications facing stem cell therapy, 
tumorgenesis.
Aside for the risk of essentially causing tumor formation, stem 
cell therapy may also affect the growth and formation of existing 
tumor cells. If, for example, a patient has a dormant tumor of 
cancerous cells, stem cell therapy may active it. This has not 
been proven but is under investigation with the use of mouse 
stem cells. 
Immune Response
Any donation requires proper human leukocyte antigen match-
ing (HLA); stem cell therapy is no different. Taking care to ensure 
that the donor and recipient match decreases the risks of Graft 
Verse Host Disease (GVHD). As detailed in table one, some 
forms of stem cell therapy are allogeneic. Therapies that are not 
recognized by the body risk immune rejection. Even those that 
are immune privileged (hESC) may be subject to rejection and/
or an inflammatory response due to the increase in response 
stimulus, caused by the actual stem cell therapy induction. For 
that reason, stem cell therapy may be administered while the 
patient is on immune suppressants. Placing a patient on immune 
suppressants runs the risk of adverse drug reactions. There are 
ongoing studies investigating different methods of stem cells 
growth in vivo that will limit the risk of rejections and GVHD. 
Such studies include introduction of mesenchymal stem cells 
in vivo. Data from such research indicated that these stem 
cells tranquilize the immune system and regulate its responses 
(Herberts et. al. 2011).
Teratoma
A teratoma is a benign mass composed of a hazardous mix-
ture of tissues, generally resembling remnants of all three germ 
layers. It is established in vivo and assumed to be congenital. 
Being that pluripotent stem cells can create all three layers, 
this therapy is susceptible to such a risk. In fact the same char-
acteristics that defines stem cell, pluripotency, are the same 
trait that creates teratomas.  Research produced in 2011 
details the comparative affects of tumor formation on both 
hESC and iPSC. The research indicates that because iPSC is a 
stem cell engineered in vitro and thus a more controlled cell 
than hESC, iPSC is less susceptible to tumor genesis. In fact 
the reason that teratomas are found less frequently in iPSC is 
because the heterogeneity of this cell causes slower growth 
rate (Zhang et. al. 2012).  
In addition to cell type effects on teratomas, injection sites may 
also influence distinctive increase or decrease levels of forma-
tion. Although not enough clinical research and analysis can con-
fidently support this claim, it is reasonable (Zhang et. al. 2012). 
More research has been performed on mouse stem cells to 
detect the correlation of the environment in which the stem 
cells are injected into and malignant tumors. Although tumor 
growth differs from teratomas, these discoveries may lead to 
additional exploration into the plausible affect of increased ter-
atomas based off of site administration (Herberts et. al. 2011).  
Success
Success is a complicated term to define when associating 
it with ongoing scientific research. Success can be attributed 
to a research breakthrough or a clinical accomplishment; it’s 
simply relative. Longevity is fundamental determinate of suc-
cess.  Pluripotent haematopoietic stem-cell transplantation for 
cancer therapy has made significant stride since initial investi-
gations over sixty years ago. It progressed from research that 
was plagued with complications and hurdles to a standard form 
of treatment. This blood forming stem cell is the only therapy 
approved for standard use because of sufficient understand-
ing of the cells, possible complications, and long term affects. 
Expansion of this therapy for use other than replacement of 
blood and immune cells causes similar complications mentioned 
throughout this document. There are many trials taking place 
and success may be recognized within each trial but a complete 
understanding of overcoming challenges and complications can 
only be determined by continual research and the test of time 
(Stem Cell Information, n.d.).
Conclusion
Research, along with case studies and accounts show there are 
far more complications with stem cells than would appear at 
first glance; they require numerous forms of adjustments to 
insure an innocuous treatment. Limiting stem cell therapies is 
a promising prospect, and in some therapies it has been suc-
cessful. However, there is insufficient research completed at this 
time to form a definite universal response for limiting any form 
of stem cell for every therapy application. 
Researchers are investigating the factors that cause the risks 
involved in various therapies and consequently exploring rem-
edies and suggestive solutions. However, stem cell therapies 
involve a multitude of complexities, some yet to be ascertained. 
The reason for these uncertainties appears to be based on the 
varied potential administrations, forms of stem cells (hESC, iPSC, 
ntES), their associated risks, and the limitless therapies they can 
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produce. This research is a relatively new and revolutionary 
field of study. With increase research, funding, and integration 
of continual findings, selectively listed in this paper, scientists 
are advancing to the goal of utilizing all that stem cells have 
to offer. This includes the capability to understand its potential, 
related limitations, and safely developing the two in an effort to 
advance medicine. Stem cell therapy is the promise for infinite 
preventative care and treatment options.
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